King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
21:41
The mayor of Cluj-Napoca, Emil Boc, condemns the attack on the ambulance and calls for regulation of social networks.
21:13
Eugen Tomac: "The president is ready to appoint a candidate tomorrow if he announces that he has a solid majority backing him."
20:55
The Ministry of Energy announces the first effects after the sinking of the four barges in the Danube
20:13
Study: Europe is not prepared for Russia's drone attacks
19:58
Irinel Scrioșteanu, after the sinking of the barges in the Danube: A hard-fought battle, good result, but the danger has not passed [...] the currents of the Danube are strong and can be very unpredictable.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
